Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials
2023 · Nature Medicine · 348 citations
https://doi.org/10.1038/s41591-022-02103-8
E
Ecaterina E. Dumbrava
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
335
Papers
2.3K
Citations
22
h-index
42
i10-index
Ecaterina E. Dumbrava is an academic researcher from The University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Cancer Genomics and Diagnostics & Cancer Immunotherapy and Biomarkers. The author has an h-index of 22, co-authored 285 publications.
ORCID: 0000-0002-1959-0536Papers by this author
worksPhase 2 study of pembrolizumab in patients with advanced rare cancers
2020 · Journal for ImmunoTherapy of Cancer · 127 citations
https://doi.org/10.1136/jitc-2019-000347
HER2-low expression in patients with advanced or metastatic solid tumors
2023 · Annals of Oncology · 66 citations
https://doi.org/10.1016/j.annonc.2023.08.005
Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors
2022 · ESMO Open · 39 citations
https://doi.org/10.1016/j.esmoop.2022.100573
PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers
2021 · ESMO Open · 38 citations
https://doi.org/10.1016/j.esmoop.2021.100230
PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial
2024 · Nature Communications · 32 citations
https://doi.org/10.1038/s41467-024-53220-6
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat